Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

<p>Genomic landscape in patient-derived preclinical models. The genetic alteration of the PDC (patient-derived cell), PDO (patient-derived organoid), and PDX (patient-derived xenograft) models are shown as an oncoprint plot.</p>

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Seung Yeon Oh (15051017) (author)
مؤلفون آخرون: You Won Lee (15051020) (author), Eun Ji Lee (15051023) (author), Jae Hwan Kim (15051026) (author), YoungJoon Park (15051029) (author), Seong Gu Heo (15032490) (author), Mi Ra Yu (15051032) (author), Min Hee Hong (15014541) (author), John DaSilva (15051035) (author), Christopher Daly (15030374) (author), Byoung Chul Cho (15032496) (author), Sun Min Lim (15051038) (author), Mi Ran Yun (15032484) (author)
منشور في: 2025
الموضوعات:
Cancer
Therapeutic Research and Development
Drug Resistance
Clinical drug resistance
Lung Cancer
Translational Research
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا

مواد مشابهة